A67 Abstracts was performed. Cronbach's alpha coefficients and Pearson's product moment correlations were calculated to estimate reliability. To establish construct validity, correlation coefficients were calculated between the subscales and vitality, well-being, treatment satisfaction, and/or baseline glycosylated hemoglobin (HbA1c). Standard errors of measurement (SEMs) were calculated to estimate minimal important difference. RESULTS: In both studies: 1) factor analysis confirmed the factor structure of the four subscales with the exception that the "sleepiness or drowsiness" item loaded with the Fatigue subscale items rather than the Cognitive Distress items; 2) test-retest reliability (all >0.68) and Cronbach's alpha coefficients (all >0.79) were acceptable; 3) associations between subscales and other patientreported outcomes measures and/or HbA1c were significant (p < 0.05) and in the hypothesized directions; and 4) SEMs were approximately 0.5 on a 1 to 5 scale. CONCLUSION: Preliminary validation indicates that the Cognitive Distress, Fatigue, Hyperglycemia, and Hypoglycemia subscales are potentially reliable and valid individual measures for use in clinical trials evaluating antihyperglycemic medications in patients with type 1 or type 2 diabetes.
Sundaram M, Miller LA, Kavookjian J West Virginia University School of Pharmacy, Morgantown, WV, USA OBJECTIVES: This study reports relationships between two instruments of health status and an instrument of quality of life (QoL) in a cross-sectional study among patients with Type 2 Diabetes Mellitus (T2DM). METHODS: Of generic health status (SF-12 and EuroQoL EQ-5D), and diabetes-specific QoL (Audit of Diabetes Dependent Quality of Life-ADDQoL). Patient reported data were merged with retrospective clinical data including A1C, comorbidities, diabetes complications score, BMI, and others, from electronic medical records. RESULTS: Usable response rate was 44.3% (n = 385). Mean A1C of respondents was 7.2 (+1.4), mean diabetes duration was 10.2 (+9.1) years, and 62.1% were obese (BMI >30). About 49% of respondents were on oral medications only, 31.7% on oral medications and insulin, and 9.4% on insulin only. Spearman correlations of the EQ-5D were 0.640 with the SF PCS-12, 0.534 with the SF MCS-12, and 0.316 with the ADDQoL (all p < 0.001). Insulin use and diabetes-related complications were significantly associated with poorer scores on all measures. Only ADDQoL scores were significantly better among those with the ADA recommended A1C level <7.0 (p = 0.002). Nearly 73% respondents reporting moderate problems with mobility and usual activities on the EQ-5D were clinically obese. Obesity significantly impaired SF-12 scores but not ADDQoL scores. A path analytic model relating SF-12 scores with EQ-5D and ADDQoL scores had good fit (Chi sq. = 1.32, p = 0.250; TLI = 0.99; RMSEA = 0.03). CONCLUSION: All three measures discriminated on the basis of diabetes treatment group and number of complications. Health status was impaired by obesity in T2DM. Those patients with poorer glycemic control had lower scores on the diseasespecific QoL instrument. The health status and QoL instruments used in the study appeared to measure different constructs, confirming past recommendations about their complementary use in diabetes populations. To compare self-report measures of medication adherence with claims-based measures of adherence. METHODS: A mail survey was conducted of persons with diabetes in the Henry Ford Health System in 2006. Prescription claims were obtained for survey respondents, and the analyses were conducted with 932 persons who were using at least two oral medications for diabetes. The self-reported measures of adherence included a six-category self-rating of adherence which ranged from "never" to "all of the time" and a visual analog scale (VAS) wherein patients marked the percentage of time that they followed the medication regimen as directed The claimsbased measure was the continuous measure of availability (CMA) reported as a scale from 0 to 100%. Two dichotomous measures of adherence were created: CMA-80 (CMA cut at 80%); VAS-80 (VAS cut at 80%). RESULTS: The VAS and CMA demonstrated a linear relationship in the expected direction with the self-selected categories for medication adherence. The mean VAS scores ranged from 62.4% to 98.1% across the categories (F = 180.4, p < 0.001), and the CMA ranged from 66.1% to 85.4% (F = 15.8, p < 0.001). The VAS had a moderate correlation with the CMA (r = 0.25). The mean (±SD) for the VAS and CMA were 95.5 (±10.4) and 83.2 (±15.9), respectively. For difference scores (VAS minus CMA), 33.5% of respondents had a VAS that was at least 1 SD higher than CMA. When comparing the VAS-80 to the CMA-80, the area under the ROC curve was 0.54 (2.3% were categorized as adherent by CMA-80, but nonadherent by VAS-80; 30.2% were categorized as non-adherent by CMA-80, but adherent by VAS-80). CONCLUSION: Selfreported adherence to medications by patients with diabetes is moderately correlated with claims-based estimates. However, about one-third of respondents will have a VAS that is significantly higher than CMA.
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PDB27 MEDICATION ADHERENCE IN PATIENTS WITH DIABETES DURING THE MEDICARE PART D BENEFIT COVERAGE GAP PERIOD
Prasla K 1 , Godley P 1 , Rascati KL 2 , Gabrillo E Patients were excluded if they subsequently experienced catastrophic coverage or did not reach the coverage gap during 2006. Medication adherence was measured using pharmacy claims data to calculate medication possession ratios (MPR). A descriptive comparison of MPR during "pre-coverage gap days" and
